← REGULATORY CHANGES
FEDERAL REGISTER · RULEDecember 26, 2024IN FORCE

Nonprescription Drug Product With an Additional Condition for Nonprescription Use

What this record is not

Document details are published in the U.S. Federal Register; SPEQ surfaces them for reference and is not affiliated with or endorsed by the FDA or the Office of the Federal Register. The authoritative text is on federalregister.gov.

STATUSIN FORCE
EFFECTIVEJan 27, 2025
COMMENTS CLOSE—
APPLIES TO · SPEQ TAGDrug
Document type
Rule
Agency
Health and Human Services Department
Published
December 26, 2024
Effective
January 27, 2025
Document number
2024-30261
CFR references
21 CFR 201, 21 CFR 314
Docket
FDA-2021-N-0862
RIN
0910-AH62
ABSTRACT

The Food and Drug Administration (FDA, the Agency, or we) is issuing a final rule to establish requirements for a nonprescription drug product with an additional condition for nonprescription use (ACNU). A nonprescription drug product with an ACNU is a drug product that could be marketed without a prescription if an applicant implements an additional condition to ensure appropriate self-selection or appropriate actual use, or both, by consumers without the supervision of a practitioner licensed by law to administer such drug. The final rule is intended to increase options for applicants to develop and market safe and effective nonprescription drug products and increase consumer access to appropriate, safe, and effective drug products, which could improve public health.

Abstract as published in the Federal Register.

READ THE FULL DOCUMENT

The complete document — every provision, the docket, and the comment instructions — is published in the Federal Register. SPEQ surfaces and indexes it for reference; the authoritative text lives on federalregister.gov.

View on federalregister.gov →

That is what FDA published. A free account files it on your watchlist and sends one weekly email with whatever lands next.

Create a free account